texts stringlengths 189 3.2k | labels class label 3
classes | embeddings sequence |
|---|---|---|
provision for estimated shortfall, if any, on minimum revenue sharing payments is made in the period in which the shortfall becomes probable and can be reasonably estimated. Under the revenue sharing agreements for our DVD library, at the end of the Title Term, we generally have the option of returning the DVD to the s... | 0BUY | [
-0.014290396124124527,
0.031452104449272156,
-0.012414602562785149,
-0.0038040638901293278,
-0.07683157175779343,
-0.015884626656770706,
0.0033224960789084435,
-0.006076224613934755,
0.036492668092250824,
0.02067665196955204,
0.021916106343269348,
-0.10512056946754456,
0.0009348664898425341,... |
Lease Classification or Measurement under Statement 13 and FSP No. FAS 157-2 , Effective Date of FASB Statement No. 157 . FSP 157-1 amends SFAS No. 157 to remove certain leasing transactions from its scope. FSP 157-2 delays the effective date of SFAS No. 157 to fiscal years beginning after November 15, 2008 for all non... | 0BUY | [
-0.020036345347762108,
0.017301464453339577,
-0.007460196036845446,
-0.012839315459132195,
-0.08300543576478958,
-0.01426804717630148,
-0.0024365494027733803,
-0.009719794616103172,
0.033330775797367096,
-0.011308085173368454,
-0.01605241373181343,
-0.09600110352039337,
0.007047166582196951,... |
timing of payments in connection with these tax liabilities; therefore, such amounts are not included in the above contractual obligation table.
Indemnifications
The Company generally does not indemnify end-users of its operating system and application software against legal claims that the software infringes third... | 0BUY | [
-0.02061433717608452,
0.012805606238543987,
-0.008130966685712337,
0.02677847445011139,
-0.08278032392263412,
-0.005866856314241886,
-0.001056445064023137,
0.0019039969192817807,
0.03714694827795029,
0.007686012890189886,
0.02266731671988964,
-0.08876892924308777,
0.01206823531538248,
0.00... |
long-term investment return that meets or exceeds a 9% annualized return target. The impact of a 0.50% change in our expected long-term rate of return is shown in the table below.
For additional information about our pension plans, see Note 10 of the Notes to the Consolidated Financial Statements.
Recently Issued ... | 1HOLD | [
-0.007369794882833958,
0.049504801630973816,
0.00507583562284708,
0.028649065643548965,
-0.13780030608177185,
-0.01041488815099001,
-0.01103738322854042,
0.005467419978231192,
-0.06689302623271942,
0.011537808924913406,
0.014624089933931828,
0.016317876055836678,
0.023632578551769257,
-0.0... |
increase reflects a 7% increase in headcount-related costs, a 25% increase in third-party product development costs, and a 29% increase in testing laboratory equipment and expense. In fiscal 2002, research and development expenses were $4.31 billion compared to $4.38 billion in fiscal 2001. The decrease from fiscal 200... | 1HOLD | [
-0.00514434976503253,
0.03540223464369774,
0.01683386228978634,
0.03319515660405159,
-0.07919028401374817,
-0.006233347579836845,
0.00015702718519605696,
-0.02142838016152382,
-0.06250444054603577,
-0.003930759150534868,
-0.014919377863407135,
0.022348739206790924,
0.01258164830505848,
-0.... |
anticipate doing so in the foreseeable future. The aforementioned inputs entered into the option valuation model we use to fair value our stock awards are subjective estimates and changes to these estimates will cause the fair value of our stock awards and related stock-based compensation expense we record to vary.
... | 1HOLD | [
-0.0009696943452581763,
0.04239148274064064,
0.016573041677474976,
0.012416751123964787,
-0.09035742282867432,
0.004617330152541399,
-0.009174840524792671,
-0.0092135826125741,
-0.03910456970334053,
-0.0012668212875723839,
0.01126041915267706,
-0.00028860406018793583,
0.0333373099565506,
-... |
application processor is an area where we can add a significant amount of value and we also believe it represents a revenue growth opportunity.
Gross Margin Improvement
We continued to focus on improving our gross margin in fiscal year 2008. Our gross margin was 45.6% for fiscal year 2008, an increase of 320 basis... | 2SELL | [
-0.0032654888927936554,
0.05248303711414337,
-0.0063798632472753525,
-0.03105979412794113,
-0.1071443110704422,
-0.019562508910894394,
-0.0036152552347630262,
0.008238757029175758,
-0.05907367914915085,
0.036130040884017944,
0.006944018416106701,
-0.021681351587176323,
0.01955585554242134,
... |
2009
Management’s Discussion and Analysis of Financial Condition and Results of Operations
We begin Management’s Discussion and Analysis of Financial Condition and Results of Operations with an overview of our key operating business segments and significant trends. This overview is followed by a discussion of our cri... | 1HOLD | [
-0.004990001674741507,
0.038877010345458984,
0.012078644707798958,
0.0390491746366024,
-0.05470382422208786,
-0.006276481319218874,
-0.009304511360824108,
-0.010714875534176826,
-0.047833915799856186,
-0.010947109200060368,
0.017611727118492126,
0.0505903996527195,
0.023697635158896446,
0.... |
with post-herpetic
neuralgia April 2010 —
Revatio Application submitted in the EU for pediatric PAH — February 2010
Apixaban Application submitted in the EU for prevention of venous thromboembolism — February 2010
Xalacom Approval in Japan for the treatment of glaucoma January 2010 —
Prevenar 13 Ap... | 2SELL | [
-0.0025122410152107477,
0.0605895072221756,
-0.0031086390372365713,
-0.01855449378490448,
-0.1125393807888031,
-0.014571341685950756,
-0.002549955388531089,
0.005749716889113188,
-0.06818185746669769,
0.029641637578606606,
0.0038994471542537212,
-0.019455982372164726,
0.015970833599567413,
... |
to operations of $21 million. The net restructuring charge of $18 million recognized during the fourth quarter of 1999 reflects $3 million of excess reserves related to prior restructuring actions. The $21 million cost of these actions was comprised of $11 million for contract cancellation charges associated with the c... | 0BUY | [
-0.014897252433001995,
0.04827296361327171,
-0.00636580353602767,
0.02313835173845291,
-0.12462721019983292,
-0.0023494346532970667,
-0.0019341029692441225,
-0.005585655570030212,
-0.028194276615977287,
-0.00018812213966157287,
-0.012884112074971199,
-0.03368160128593445,
0.02581768482923507... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 19